Why the study?
Does valsartan reduce blood pressure and improve tolerability compared to captopril in adult Indonesian outpatients with essential hypertension?
Does valsartan reduce blood pressure and improve tolerability compared to captopril in adult Indonesian outpatients with essential hypertension?
Valsartan provides comparable blood pressure reduction to captopril but eliminates the risk of ACE inhibitor-induced dry cough in Indonesian patients.
Supports preferring valsartan to captopril for better early BP normalization and cough-free tolerability; extends ARB vs ACEI RCT evidence to Indonesian outpatients.
Adult Indonesian outpatients were randomised to receive either valsartan 80 mg once daily or captopril 25 mg twice daily for 8 weeks. The main criterion for tolerability was the incidence of adverse events. The primary efficacy variable was the change in mean sitting diastolic blood pressure (SDBP) from baseline to endpoint. No valsartan patients experienced dry cough, which was reported by 22 captopril patients (21.6%). Both drugs reduced mean SDBP and SSBP, with a trend in favour of valsartan. The percentage of valsartan patients whose BP normalised was higher than in captopril patients at week 4 (37% and 22%) and week 8 (45% and 34%), the difference being statistically significant at week 4 (p < 0.05). Valsartan 80 mg once daily is as effective as captopril 25 mg twice daily in reducing blood pressure in Indonesian patients, and has a better tolerability profile in respect of dry cough.
No takes yet. Share an insight, caveat, or question.
Prabowo et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: